Harrow (HROW) Stock Price, News & Analysis

Harrow, Inc. (Nasdaq: HROW) is an eyecare-focused pharmaceutical company that describes itself as a leading provider of ophthalmic disease management solutions in North America. According to the company, it offers a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, including dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, a range of ocular surface conditions, and retina diseases. Harrow states that it was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Harrow operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. The company’s business is centered on the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. In earlier disclosures, Harrow has described two operating segments: a Branded segment, which includes activities related to FDA-approved ophthalmology pharmaceutical products and the out-licensing of rights to certain branded products, and the ImprimisRx segment, which represents activities in its ophthalmology-focused pharmaceutical compounding business.

Harrow emphasizes that its portfolio spans prescription and non-prescription ophthalmic medications, intended to make eyecare therapies accessible and affordable to millions of Americans. Through its ImprimisRx subsidiary, the company has highlighted its role in ophthalmic compounding and its history of providing compounded medicines used by eyecare professionals across the United States. Harrow characterizes ImprimisRx as a trusted national leader in ophthalmic compounding and notes that it has supplied critical, affordable medicines to many patients over a period of years.

In addition to its established ophthalmic portfolio, Harrow has taken steps to expand into related therapeutic areas. The company has announced the acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on non-opioid, non-intravenous (non-IV) therapies for sedation for medical procedures in hospital, outpatient, and in-office settings. Melt’s product candidates, including MELT-210, MELT-300, and MELT-400, are based on the Zydis oral dissolving tablet (ODT) drug delivery platform. Harrow has stated that MELT-300 is a patented, sublingually delivered formulation of a fixed dose of midazolam and ketamine designed to provide rapid, predictable sedation without the need for IV administration, with potential applications in ophthalmology and other medical specialties.

Harrow links this acquisition to its existing perioperative and surgical offerings. The company has previously marketed MKO Melt, a compounded sublingual sedation product sold by ImprimisRx and used by U.S. ophthalmic institutions, primarily for cataract surgery. Harrow has indicated that MELT-300 builds on real-world experience with MKO Melt and has been studied in Phase 2 and Phase 3 clinical programs. The company has described MELT-300 as having demonstrated statistical superiority to midazolam alone in completed clinical trials, and it has outlined plans to pursue a New Drug Application (NDA) and potential commercialization in the United States.

Beyond product development, Harrow has also described initiatives focused on patient access and affordability. The company has launched the VEVYE Access for All (VAFA) program to improve access and affordability for VEVYE (cyclosporine ophthalmic solution) 0.1%, a prescription medication indicated for the treatment of the signs and symptoms of dry eye disease. Building on VAFA, Harrow announced Harrow Access for All (HAFA), which it characterizes as an expansion of its patient access model across its broader ophthalmic portfolio of branded, authorized generics (AGx), and compounded medications. According to Harrow, HAFA is intended to provide a single, unified access point for prescribers and patients, with features such as predictable pricing, streamlined prescribing, and integration with electronic medical record systems.

Harrow has also discussed a digital access platform, referred to as the HarrowAccess.com portal, which it describes as a centralized portal for its specialty, generic, and compounded ophthalmic medications and partner products. The company states that this platform is designed to simplify prior authorizations, reduce administrative burden for prescribers, and provide a more predictable path from prescription to treatment for patients.

From a capital structure and financing perspective, Harrow has reported activities related to debt offerings and credit facilities. The company has announced the pricing of senior unsecured notes due 2030 and the establishment of a senior secured revolving credit facility with a commercial bank. According to Harrow’s disclosures, the proceeds from these notes are expected to be used to repay existing debt, redeem previously issued senior notes, and support general corporate purposes, which may include strategic business development opportunities and related investments. Separate Form 25 filings indicate the removal from listing of certain Harrow senior notes (with specific coupon and maturity profiles) from the Nasdaq Stock Market, following redemption.

Harrow is headquartered in Nashville, Tennessee, and its common stock trades on the Nasdaq Stock Market under the symbol HROW. The company regularly communicates with investors through press releases, investor conferences, and an Investor & Analyst Day, where it provides overviews of its commercial portfolio, development pipeline, and long-term vision. Harrow’s public communications frequently reiterate its focus on ophthalmic disease management, patient access, and the development and commercialization of ophthalmic and related pharmaceutical products.

Business segments and focus areas

According to prior descriptions, Harrow’s operations include:

• Branded ophthalmic products – FDA-approved ophthalmology pharmaceutical products and related out-licensing activities.
• ImprimisRx ophthalmic compounding – an ophthalmology-focused pharmaceutical compounding business that supplies compounded medications to U.S. eyecare professionals.
• Perioperative and procedural sedation candidates – through the acquisition of Melt Pharmaceuticals, focusing on non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210, with potential use in ophthalmic and other outpatient procedures.
• Access and affordability programs – initiatives such as VAFA and HAFA, which are designed to improve patient access to Harrow’s branded, generic, and compounded ophthalmic medications.

Position within ophthalmic care

Across its disclosures, Harrow consistently frames its role as supporting U.S. eyecare professionals in preserving sight by making ophthalmic medications accessible and affordable. The company highlights its focus on both anterior segment conditions (such as dry eye disease, cataracts, refractive errors, and ocular surface disease) and posterior segment or retina conditions (including wet age-related macular degeneration and other retina diseases). Harrow’s communications also emphasize its interest in addressing unmet needs in ophthalmology and related procedural settings, particularly where non-opioid, needle-free sedation and streamlined access to medications may benefit patients and providers.

FAQs